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Summary 
Interleukin-10 (IL-10) is produced at a high level by B lymphocytes and monocytes of patients 
with systemic lupus erythematosus (SLE). In the present work, we analyzed whether this increased 
production  of IL-10 contributed to the abnormal production  of immunoglobulins  (Ig) and of 
autoantibodies  in SLE.  The role of IL-10 was compared with  that  of IL-6,  another  cytokine 
suspected to play a role in these abnormalities.  The spontaneous in vitro production  of IgM, 
IgG, and IgA by peripheral blood mononuclear  cells from SLE patients  was weakly increased 
by recombinant IL (rlL)-6, but strongly by rlL-10. This production was not significantly affected 
by an anti-IL-6 mAb but was decreased by an anti-IL-10 mAb. We then tested the in vivo effect 
of these antibodies in severe combined immunodeficiency mice injected with PBMC from SLE 
patients. The anti-IL-6 mAb did not significantly affect the serum concentration of total human 
IgG and of anti-double-stranded DNA IgG in the mice. In contrast, the anti-IL-10 mAb strongly 
inhibited  the production  of autoantibodies,  and,  to a lesser extent,  that  of total  human  IgG. 
These results indicate that the Ig production by SLE B lymphocytes is largely IL-10 dependent, 
and that the increased production of IL-10 by SLE B lymphocytes and monocytes may represent 
a critical mechanism  in  the emergence of the autoimmune  manifestations  of the disease. 
T 
he immunological imbalance of SLE is characterized by 
an increased B lymphocyte hyperactivity,  mainly reflected 
by the production of autoantibodies (1) and decreased in vitro 
and in vivo cellular immune responses (2, 3). The latter de- 
fect is related to a dysfunction of both T helper lymphocytes 
(4) and antigen-presenting cells (5). IL-10 is a potent in vitro 
inducer of B lymphocyte differentiation (6) as well as an in- 
hibitor of T  helper lymphocyte (7)  and antigen-presenting 
cell function (8). Thus, the immunological imbalance of SLE 
may be related to an abnormally high production of IL-10, 
or to a hypersensitivity  of immune  cells  to this  cytokine. 
Consistent with the putative implication of IL-10 in the 
pathophysiology of SLE,  we recently  showed that  SLE is 
characterized by an increased production of IL-10 by PBMC. 
In untreated SLE patients, PBMC spontaneously express the 
IL-10 gene at a significantly higher level than that in healthy 
individuals.  Moreover, PBMC from SLE patients spontane- 
ously release large amounts of IL-10. T lymphocytes are not 
involved in the hyperproduction of IL-IO, which arises from 
both B lymphocytes and monocytes (9,  10).  These results 
suggest that B lymphocyte hyperactivity in human SLE results 
from the conjunction of IL-10-mediated autocrine and para- 
crine  stimulations. 
Murine studies suggest a role for IL-10 in the pathophysi- 
ology of SLE. Treatment of NZB/W F1 mice with an anti-IL- 
10 mAb delays the onset of autoimmune manifestations and 
the production of autoantibodies (11). However, the role of 
IL-10 as an inducer of autoantibody production in human 
SLE  has  not yet been documented. 
In addition  to IL-10,  IL-6 has  been suggested to be in- 
volved in the induction of autoimmune manifestations  of SLE. 
Indeed,  serum concentrations  of IL-6 are  high  in SLE pa- 
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and production  of autoantibodies  in SLE are at least partly 
IL-6 dependent  (12). 
We investigated the respective effects of rlL-6, rlL-10, as 
well as neutralizing  anti-IL-6 and anti-IL-10 mAbs, on the 
production  of total Ig and  autoantibodies  in SLE patients. 
These questions were addressed by experiments both in vitro 
and  in  vivo using  the  SCID mouse model. 
Materials and Methods 
Patients.  17 patients were included in the study. All were women 
and they fulfilled  at least four of the American College of Rheu- 
matology criteria for SLE (13). Their ages ranged from 21 to 46 
yr (mean 33.8 yr). They had received  no immunosuppressive or 
corticosteroid treatment during the previous month, and no non- 
steroid antiinflammatory drugs for at least 3 d. Clinical disease ac- 
tivity was scored on a 0-16 point scale according to the Mex-SLEDAI 
index (14). 2 patients had inactive disease; 3 patients, with indices 
of 1-2, were grouped as having mild active disease;  12 patients, 
with indices  of 7-16,  had severe multisystem disease.  19 healthy 
female volunteer blood donors served as control subjects.  All pa- 
tients and controls were informed about the objectives and methods 
of the study and gave their consent. 
Reagents.  Human recombinant IL-6 was kindly provided by N. 
Vita (Sanofi Bio Recherches,  Lab~ge, France).  Human recombinant 
II.-10 was provided by K. Moore (DNAX, Palo Alto, CA). The 
neutralizing anti-IL-6 mAb (BE-8) has already been described  (15). 
The neutralizing anti-IL-10 mAb (B-N10, IgG1) was obtained by 
fusing P3X63-Ag8.653 mouse myeloma cells to spleen cells from 
Balb/c  mice  immunized  with  human  recombinant  ILl0.  The 
screening for specific antibodies was performed by ELISA: Hy- 
bridoma supernatants were incubated in microtiter plates  coated 
with a goat anti-mouse antibody followed by incubation with bio- 
tinylated IL-10. The assay was then terminated with streptavidin 
peroxydase  and substrate. Several antibodies were selected  in this 
assay, and B-N10 was chosen for its ability to block ILl0 activity 
in a bioassay. In the latter,  PBMC (4.106 cells/ml) were activated 
for 24 h with LPS (1 #g/ml) in the absence or presence of Ibl0 
(1 ng/ml) and of graded concentrations of anti-IL-10 mAb. The 
inhibition of IL-6 production by II.-10 was determined in the su- 
pernatants of these cultures by an Ib6-specific ELISA. 500 ng B-N10 
was needed to neutralize  the activity of 1 ng ILl0. 
As control antibodies, we used, for in vitro studies,  the anti- 
KLH mAb (Becton Dickinson and Co., Mountain View, CA) and, 
for SCID mice studies,  the F3.14.1 mAb (recognizing the hepatitis 
B virus [HBV] ~ envelope protein). This antibody was obtained by 
fusing P3X63Ag-8.653 myeloma cells with spleen cells from Balb/c 
mice immunized with 42-nm viral particles purified from the serum 
from an HBV-infected patient.  The screening of the clones  was 
performed using a radioimmunoassay in which HBV particles were 
coated, the clone supernatants were added to the wells,  and the 
fixation of the mAb was revealed using anti-mouse Ig antibodies. 
The F3.14.1 is an IgG1 mAb which does not recognize any serum 
protein from healthy individuals  but binds in Western blot analysis 
to two HBV envelope antigens of 55 kD and 66 kD, respectively. 
Antibodies for in vitro experiments were used at the final concen- 
tration of 10 #g/ml. 
Cell Separations.  PBMC were isolated on Histopaque (Sigma 
t Abbreviatiom  used in  this paper: CM,  complete medium;  ds,  double 
stranded; HBV, hepatitis B virus. 
Chemical Co., St. Louis, MO) by gradient centrifugation. For in 
vitro  studies,  PBMC  were  rosetted  twice  with  2-aminoethyl- 
isothiouronium  bromide (Sigma)-treated  sheep  red  blood cells. 
Non-T cells were resuspended in R.PMI 1640 (Gibco Laboratories, 
Grand Island, NY) containing 100 U/ml penicillin,  2 mM gluta- 
mine,  and  10%  gammaglobulin-free fetal calf serum  (complete 
medium, CM), (GIBCO). For in vivo studies in SCID mice and 
for bcl-2 expression analysis,  PBMC were kept frozen in  liquid 
nitrogen  until  tested. 
Cell Cultures.  One million non-T cells were cultured in CM 
for 24 h, washed, and cultured for an additional 5 d. Either rib-6, 
rlL-10, anti-IL-6 mAb, or anti-Ibl0 mAb were added during each 
step of the cultures.  The concentrations of lgM, IgG, and IgA were 
measured in the supernatant using an ELISA assay. Briefly, 96-well 
flat-bottom microtitration plates (Linbro Chemical Co., Hamden, 
CT) were coated with goat anti-human polyvalent immunoglob- 
ulin (10/xg/ml) overnight at 4~  After washing and saturating 
the plastic plates with 1% bovine serum albumin in PBS, culture 
supernatants or standard human IgM, IgG, and IgA (Sigma) were 
added to the coated wells  in duplicate and incubated  for 4 h  at 
room temperature. After washing out unbound antibodies, alka- 
line  phosphatase-conjugated goat IgG, specific for human IgM, 
IgG, or IgA (Sigma), were added to correspondent wells and in- 
cubated overnight at 4~  The enzyme reaction was measured by 
its absorbance at 405  nm with a Titertek Multiscan |  microtiter 
plate  spectrophotometer (Flow Laboratories, Inc., McLean, VA). 
A paired Student's  t test was used  for statistical  analysis. 
Flow Cytometric Analysis.  Two-color flow cytometric analyses 
were performed using  a  FACScan |  (Becton  Dickinson).  Non- 
T cells were washed twice in PBS containing 2% fetal calf serum 
and stained for 20 rain at 4~  with anti-CD19 PE-conjugated mAb 
(Dako Corp., Glostrup, Denmark). Washed cells were fixed in 1 ml 
0.25% paraformaldehyde for 15 min at room temperature. Then, 
cells were permeabilized in 1 m170% methanol for I h. After two 
washes, cells were incubated with mAb anti-bcl-2 FITC (Dako), 
which had been conjugated for 20 min.  After three washes,  cells 
were analyzed. As controls, mAbs conjugated with either PE or 
FITC  and  of the  same isotype as  the  anti-CD19  or  anti-bcl-2 
mAbs were used. 
SCID  Mice Experiments.  6-10-wk-old SCID mice from Iffa- 
Credo (L'Arbresle, France),  maintained in a sterile  isolator,  were 
used.  Of the 32 SCID mice tested for murine IgG (Biosys, Com- 
pibgne, France),  two had serum levels of above 10 ng/ml and were 
excluded  from the study.  Frozen PBMC from SLE patients were 
thawed,  washed twice in  kPMI  1640,  and resuspended in PBS. 
15 million cells were injected intraperitoneally to each mouse in 
a final vol of 200/~1. The mAbs were injected intraperitoneally twice 
a week (100/~g each  time,  from day 3 to day 21). Thus,  a total 
of 600/~g mAb was administered to each mouse. On day 30, the 
mice were killed,  and the serum was collected and stored frozen 
in aliquots until tested. Total human IgG were measured using an 
ELISA assay (Biosys, Compi~gne, France), and human anti-dsDNA 
IgG were measured using a Farr assay (Kodak Diagnostic SA, Les 
Ulis, France). A paired Student's t test was used for statistical analysis. 
Results 
In  Vitro E~t  of aL-6 and aL-lO on Ig Sy,~the~is of SLE 
Patients.  Non-T cells from five healthy individuals and seven 
SLE patients  were cultured  for 24  h  in  CM,  washed,  and 
cultured  for an additional  5 d,  either alone,  or in the pres- 
ence of rlL-6 or rlL-10.  At the end of the culture,  the con- 
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pernatant. 
In healthy individuals, the spontaneous production of Ig 
was low. It was not affected by the addition of either rlL-6 
or rlL-10,  regardless of the isotype  considered (Fig.  1 A). 
The spontaneous production  of the three isotypes  by SLE 
non-T cells was much higher than that of healthy individ- 
uals' non-T cells. The addition of rlL~  only weakly stimu- 
lated this production.  The increase was, however, constant 
for both IgG and IgA (P  =  0.034 and P  =  0.043, respec- 
tively).  The  addition  of rlLol0  dramatically increased the 
production of Ig by SLE non-T cells (P =  0.02, P <  0.001, 
and P  =  0.002 for IgM, IgG, and IgA, respectively). This 
stimulating  effect of IL-10 was particularly strong for IgG 
production (the increase of which was on average [+_  SEM] 
435%  [_+  76%]  [Fig.  1 B]). 
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In Vitro Effect of an Anti-IL-6 mAb or an Anti-IL-lO mAb 
on Ig Synthesis of SLE Patients.  We then asked whether the 
endogenous production of ILo6 or IL-IO contributed to the 
spontaneous hyperactivity of B lymphocytes  from SLE pa- 
tients. Anti-IL-6 mAb did not significantly inhibit the produc- 
tion of IgM and IgG by non-T cells from SLE patients, and 
weakly inhibited that of IgA (P =  0.05).  Production of the 
three isotypes  was more sensitive to the anti-IL-10  mAb, 
which on average inhibited the production of IgM, IgG, and 
IgA by 54.2 _+ 9.5%, 44.6  _+ 7.7%, and 60.5 _+ 7.1%, respec- 
tively (P =  0.015, P  =  0.005,  and P  =  0.004, respectively) 
(Fig. 2 B).  Neither the anti-IL-6  nor the anti-IL-10  mAb 
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Figure  1.  Effect  of rlL-6  and rib10  on the in vitro production  of Ig 
by normal and SLE PBMC.  Non-T cells from either healthy individuals 
(n  =  5) (A), or SLE patients (n  =  7) (B) were cultured alone for 24 h, 
then washed and cultured for an additional 5 d either alone, in the pres- 
ence of rib6 (4 ng/ml), or in the presence of rIL-10 (10 ng/ml). The con- 
centrations  of lgM,  IgG,  and IgA in  the  supernatant  were then deter- 
mined.  Results  are expressed  as means  _+  SEM. 
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Figure  2.  Effect  of an anti-IL-6  mAb and of an anti-IL-10  mAb on the 
in vitro production of Ig by normal and SLE PBMC.  Non-T cells from 
either healthy individuals (n  =  5) (A), or SLE patients (n  =  7) (B) were 
cultured for 24 h in the presence of a control  mAb, an anti-IF6  mAb, 
or an anti-lbl0 mAb. They were then washed and cultured with the same 
mAb for an additional 5 d.  The concentrations  of IgM,  IgG, and IgA 
were then determined in the supernatant. Results are expressed as means 
_+  SEM. 
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healthy individuals  (Fig.  2 A). 
These in vitro experiments showed that the spontaneous 
production of Ig by SLE B lymphocytes is particularly sensi- 
tive to IL-10, and that the increased synthesis of this cytokine 
by non-T cells contributes to the spontaneous B lymphocyte 
hyperactivity of SLE patients. 
Expression of bcl-2 by SLE B Lymphocytes  in the Presence of 
an Anti-IL-lO mAh  The findings described above may reflect 
an  effect of IL-10 on B lymphocyte differentiation  of SLE 
patients.  Alternatively,  they may result from an increased bd-2 
expression and B lymphocyte survival (16, 17). We thus ex- 
amined, by double labeling flow cytometry analysis, the effect 
of an  anti-IL-10  mAb on the level of bcl-2 expression by 
B lymphocytes. 
In the absence of anti-IL-10 mAb, >90% of SLE B lym- 
phocytes cultured for 3 d contained bcl-2. Of the two healthy 
individuals tested, one had 94% of the B lymphocytes which 
expressed bcl-2, whereas the other had 51% bcl-2-positive 
B lymphocytes. Presence of the anti-IL-10 mAb during the 
culture did not affect bcl-2 expression by B lymphocytes from 
either healthy individuals, or SLE patients (Fig.  3). Consis- 
tent with this finding, cell viability and recovery at the end 
of the culture were unaffected by the presence of the anti-IL- 
10 mAb  (data not  shown). 
Effect of the Anti-IL-6  and Anti-IL-lO  mAbs on IgG and 
Autoantibody  Production  by  SLE  Cells  in  the  SCID  Mouse 
Model.  We then  asked whether  the in vitro  effect of the 
anti-IL-6 and anti-IL-10 mAbs on the B lymphocyte hyper- 
activity of SLE patients could be extended to an in vivo model. 
PBMC from individual SLE patients were injected into two 
or three SCID mice, which were subsequently treated with 
either a control mAb, an anti-IL-6  mAb, or an anti-IL-10 
mAb. 
On day 30, human IgG were detected in the serum of all 
mice, although  at a variable level.  As compared to control 
mice, total human IgG concentration was decreased in mice 
treated with the anti-IL-6 mAb or with the anti-IL-10 mAb. 
However, the decreases  were moderate (P >  0.1  and P  = 
0.047,  respectively) (Fig.  4 A). 
Anti-double-stranded  (ds)DNA IgG was detected in the 
serum of all mice treated with the control mAb. Treatment 
of SCID mice with anti-IL-6 mAb inconsistently decreased 
the serum concentration  of anti-dsDNA  IgG.  In contrast, 
administration of anti-IL-10 mAb consistently decreased au- 
toantibody concentration, which dropped below the threshold 
level of detection of 10 out of 12 cases (P <  0.001) (Fig.  4 
B). This indicates that in vivo, in the SCID mouse model, 
the production  of autoantibodies by SLE PBMC is largely 
dependent on the endogenous production of IL-10, whereas 
endogenous production of IL-6 does not make a major con- 
tribution. Moreover, anti-IL-10 mAb affects the production 
of autoantibodies more than  that  of total  IgG. 
Discussion 
We compared the roles oflL-6 and IL-10, two major B lym- 
phocyte-differentiating cytokines, on the polyclonal Ig secre- 
tion and on the autoantibody production  of SLE patients. 
These experiments underlined  the prominent  role of IL-10 
rather  than  that  of IL-6 on these phenomena.  In vitro ex- 
periments analyzing the spontaneous production of Ig by SLE 
PBMC showed that IL-6 or an anti-IL-6 mAb only minimally 
affected Ig production. Consistent with these in vitro findings, 
the in vivo production  of human  IgG and of anti-dsDNA 
antibodies in SCID mice injected with SLE PBMC was not 
significantly  affected by anti-IL-6  mAb administration. 
In contrast,  the IL-10 dependency of SLE B lymphocyte 
hyperactivity was clearcut by all experimental approaches used. 
The addition of rIL-10 to SLE PBMC increased the sponta- 
neous production of all isotypes tested, particularly that of 
IgG. This enhancement of Ig production by SLE PBMC con- 
trasted with the absence of effects of IL-10 on the sponta- 
neous Ig production by PBMC from healthy individuals.  The 
differentiating effect of IL-10 on normal B lymphocytes re- 
quires preactivation of the cells with another signal,  such as 
triggering  through  CD40 or surface Ig (6).  This  suggests 
that some sort of triggering stimuli had already been given 
in vivo in SLE patients  and that  IL-10 is a limiting  factor 
for production  of Ig. 
Consistent  with  this  hypothesis,  neutralization  of en- 
dogenously produced IL-10 during cultures of SLE PBMC 
significantly decreased the production of IgM, IgG, and IgA. 
We recently showed that  IL-10 is produced at a high level 
bcl-2 
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Figure  3.  Effect  of an anti-IL-10 mAb on 
bd-2 expression  by SLE B lymphocytes.  Non-T 
cells from SLE patients were cultured for 3 d 
without (A) or with (B) an anti-IL-10 mAb. 
bcl-2 expression by CD19  + lymphocytes  was 
then determined by flow cytometry analysis. 
The  fraction of  bcl-2+CD19+  and  bcl- 
2-CD19+ cells was 48.6 and 2.4%, respec- 
tively, in A, and 45.7 and 1.6%, respectively, 
in B. Results shown are from one typical case 
of five SLE patients. E 
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Figure 4.  Effect  of an anti-IL-6 mAb and an anti- 
Ibl0 mAb on the production of human IgG and anti- 
dsDNA autoantibody  production in the SCID mice 
model. PBMC from individual SLE patients (n = 12) 
were injected into 2-3 SCID mice, which were subse- 
quently treated with a control  mAb, an anti-IL-6 mAb, 
or an anti-IL-10 mAb. On day 30, the serum concen- 
trations of total human IgG (A) and of anti-dsDNA 
IgG (B) were determined. 
by monocytes and B lymphocytes from SLE patients (9, 10). 
The present results are the first evidence that this combined 
autocrine and paracrine production is directly involved in the 
spontaneous B lymphocyte hyperactivity of SLE patients.  This 
conclusion is also supported by our results in vivo with the 
SCID mouse model (in which treatment  of the mice with 
an anti-IL-10 mAb significantly decreased the production of 
human IgG). Interestingly,  anti-IL-10 mAb had a larger effect 
on the production of anti-dsDNA IgG than on that of total 
human IgG: Anti-DNA autoantibody production was com- 
pletely inhibited  in most mice.  This indicates  that  the re- 
quirement for IL-10 may be larger for the production of au- 
toantibodies  than  for that  of other  Ig. 
We previously showed that  IL-IO increases  bcl-2 expres- 
sion by germinal center B lymphocytes and that it prevents 
their death (17).  Thus,  the enhancing effect of IL-IO on Ig 
production may have been partly due to increased B lympho- 
cyte survival.  However, we found no modification of bcl-2 
expression when culturing  peripheral  B lymphocytes from 
SLE patients in the presence of an anti-IL-10  mAb.  Thus, 
the in vitro role of IL-IO on peripheral SLE B lymphocytes 
primarily reflects its differentiating potency on such cells. This, 
however, does not rule out an in vivo role of IL-IO in SLE 
involving  an  abnormal  regulation  of B  lymphocyte bcl-2 
expression.  It is possible that  the  abnormal production  of 
IL-10 by B lymphocytes and monocytes in SLE alters  the Ig 
repertoire selection by preventing B lymphocyte cell death 
in germinal centers,  for example.  Considering the importance 
of this step in the constitution of a normal Ig repertoire, such 
a phenomenon may lead to the emergence of autoantibodies. 
This hypothesis is consistent with the observation that,  in 
mice, peripheral deletion of autoreactive B1 lymphocytes is 
abrogated when the bcl-2 gene is overexpressed by the B lym- 
phocyte compartment  (16).  Further experiments  analyzing 
the role in SLE of IL-IO on bcl-2 expression and apoptosis 
of B lymphocytes from lymphoid organs are needed to ad- 
dress this  question. 
In humans,  an  increased in vivo production  of IL-10 by 
monocytes has been reported in a number of clinical  condi- 
tions. Malignant B lymphocytes are potent producers of IL- 
10 in vivo (18).  However, in vivo production  of IL-10 by 
nonmalignant B cells has been observed only in clinical con- 
ditions associated with B lymphocyte-mediated autoimmu- 
nity (as in SLE, rheumatoid arthritis, and Sj6gren's  syndrome 
[9,  10]).  In HIV infection, another condition characterized 
by polyclonal B lymphocyte hyperactivity, peripheral B lym- 
phocytes do not significantly contribute to IL-IO production 
(19) suggesting that increased production of IL-IO could be 
restricted to B lymphocytes with autoreactive properties. This 
is consistent  with  murine  studies which have shown that 
B lymphocyte-derived IL-10 primarily  arises  from  the B1 
(Lyl+) subpopulation (20). In the murine model, the auto- 
crine production of IL- 10 may be involved in the expansion 
of autoreactive B lymphocytes (21). Our present results sug- 
gest that, in SLE, a similar phenomenon may occur and that 
the abnormal production of IL-IO may contribute to the ex- 
pansion of B lymphocytes with autoreactive properties. Our 
in vitro results,  performed on non-T cells,  indicate that  T 
lymphocytes are not required for the differentiating effect of 
IL-10 on SLE B lymphocytes. Whether an additional effect 
of IL-10 on T  lymphocytes also contributes  to our results 
in  the  SCID  mice  model  cannot  be  formally  ruled  out. 
In addition  to stimulating autoreactive B lymphocytes, the 
increased  production  of IL-IO may  account  for  the  inhi- 
bition of cell-mediated immune responses observed in SLE 
patients  (2). 
In addition to monocytes and B lymphocytes, it is possible 
that extraimmunological  sources of IL-IO influence the im- 
munological  imbalance  of SLE.  In mice,  the placenta  (22) 
and UV-irradiated keratinocytes (23) produce large amounts 
of IL-IO. If this is also true in humans,  it may contribute 
to the exacerbation of SLE by pregnancy and sun exposure (24). 
These hypotheses, as well as the strong inhibition  of au- 
toantibody production  in  the SCID  mice treated  with  an 
anti-IL-10 mAb, indicate that neutralizing  the spontaneous 
production oflL-10 in SLE patients may represent a new way 
to interfere with the development of the autoimmune pro- 
cess.  Considering  the poor long-term  tolerance of the im- 
munomodulating agents currently used in this condition (24), 
this potential new therapeutic approach warrants investiga- 
tion, particularly in those patients  who require high doses 
of corticosteroids to maintain  control of the disease. 
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